智通财经APP讯， 九典制药(300705.SZ)发布公告，公司于近日收到国家药品监督管理局签发的《药物临床试验批准通知书》，在完成相关准备工作后将开展临床试验研究，涉及药品：“PDX-04”。PDX-04用于治疗痛风性急性发作镇痛的药物，目前国内外未有该产品处于临床试验阶段，国内外尚无该产品获批上市，亦无相关销售数据。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.